Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIFN-2b vs SNMC in Chronic Hepatitis C
NCT00686881Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Primary completion
- Feb 2011
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoint: Change in Metavir Fibrosis Score at 156 weeks. Started Dec 2006; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00686881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686881.